Drug Profile
UIO 512
Alternative Names: UIO-512Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Unleash Immuno Oncolytics
- Class Antineoplastics; Viruses
- Mechanism of Action Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA